OpGen (OPGN) Stock Price, News & Analysis

Company Overview

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.00 to $5.02
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 1,028 shs
• Market Capitalization: $1 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OPGN Stock Analysis - Frequently Asked Questions

How were OpGen's earnings last quarter?

OpGen, Inc. (NASDAQ:OPGN) released its quarterly earnings data on Thursday, August, 10th. The medical research company reported ($9.30) EPS for the quarter, missing analysts' consensus estimates of ($7.10) by $2.20. The medical research company earned $0.74 million during the quarter, compared to analysts' expectations of $0.90 million.

When did OpGen's stock split?

OpGen shares reverse split on the morning of Monday, May 20th 2024.The 1-10 reverse split was announced on Monday, May 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did OpGen IPO?

OpGen (OPGN) raised $17 million in an initial public offering on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group served as the underwriter for the IPO and National Securities was co-manager.

How do I buy shares of OpGen?

Shares of OPGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of OpGen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OpGen investors own include NVIDIA (NVDA), Meta Platforms (META), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Pfizer (PFE), Sorrento Therapeutics (SRNE) and Broadcom (AVGO).

Company Calendar

• Last Earnings: 8/10/2023
• Today: 9/04/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:OPGN
• CIK: 1293818
• Web: www.opgen.com
• Phone: (240) 813-1260
• Fax: 301-869-9684
• Employees: 100
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$32.67 million
• Net Margins: -1,140.36%
• Pretax Margin: -742.42%
• Return on Equity: N/A
• Return on Assets: -287.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.45
• Quick Ratio: 5.45

Sales & Book Value

• Annual Sales: $2.67 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($11.55) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 10,071,000
• Free Float: 4,696,000
• Market Cap: $1 thousand
• Optionable: Not Optionable
• Beta: -1.77